Next Article in Journal
Molecular Targets for PET Imaging of Activated Microglia: The Current Situation and Future Expectations
Next Article in Special Issue
Evaluation of the Potential Risk of Drugs to Induce Hepatotoxicity in Human—Relationships between Hepatic Steatosis Observed in Non-Clinical Toxicity Study and Hepatotoxicity in Humans-
Previous Article in Journal
Genetics of Congenital Anomalies of the Kidney and Urinary Tract: The Current State of Play
Previous Article in Special Issue
In Silico and In Vitro Analysis of Interaction between Ximelagatran and Human Leukocyte Antigen (HLA)-DRB1*07:01
Article Menu
Issue 4 (April) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2017, 18(4), 803; doi:10.3390/ijms18040803

Drug Induced Liver Injury: Can Biomarkers Assist RUCAM in Causality Assessment?

1
Department of Internal Medicine II, Division of Gastroenterology and Hepatology, Klinikum Hanau, D-63450 Hanau, Germany
2
Teaching Hospital of the Medical Faculty, Goethe University Frankfurt, D-60590 Frankfurt, Germany
3
Institute of Occupational, Environmental and Social Medicine, Medical Faculty, Goethe University Frankfurt, D-60590 Frankfurt, Germany
4
Pharmacovigilance Consultancy, F-75020 Paris, France
*
Author to whom correspondence should be addressed.
Received: 24 February 2017 / Revised: 31 March 2017 / Accepted: 1 April 2017 / Published: 11 April 2017
(This article belongs to the Special Issue Molecular Research on Drug Induced Liver Injury)
View Full-Text   |   Download PDF [2636 KB, uploaded 13 April 2017]   |  

Abstract

Drug induced liver injury (DILI) is a potentially serious adverse reaction in a few susceptible individuals under therapy by various drugs. Health care professionals facing DILI are confronted with a wealth of drug-unrelated liver diseases with high incidence and prevalence rates, which can confound the DILI diagnosis. Searching for alternative causes is a key element of RUCAM (Roussel Uclaf Causality Assessment Method) to assess rigorously causality in suspected DILI cases. Diagnostic biomarkers as blood tests would be a great help to clinicians, regulators, and pharmaceutical industry would be more comfortable if, in addition to RUCAM, causality of DILI can be confirmed. High specificity and sensitivity are required for any diagnostic biomarker. Although some risk factors are available to evaluate liver safety of drugs in patients, no valid diagnostic or prognostic biomarker exists currently for idiosyncratic DILI when a liver injury occurred. Identifying a biomarker in idiosyncratic DILI requires detailed knowledge of cellular and biochemical disturbances leading to apoptosis or cell necrosis and causing leakage of specific products in blood. As idiosyncratic DILI is typically a human disease and hardly reproducible in animals, pathogenetic events and resulting possible biomarkers remain largely undisclosed. Potential new diagnostic biomarkers should be evaluated in patients with DILI and RUCAM-based established causality. In conclusion, causality assessment in cases of suspected idiosyncratic DILI is still best achieved using RUCAM since specific biomarkers as diagnostic blood tests that could enhance RUCAM results are not yet available. View Full-Text
Keywords: drug induced liver injury; DILI; RUCAM; Roussel Uclaf Causality Assessment Method; diagnostic biomarkers; pathogenesis drug induced liver injury; DILI; RUCAM; Roussel Uclaf Causality Assessment Method; diagnostic biomarkers; pathogenesis
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Teschke, R.; Schulze, J.; Eickhoff, A.; Danan, G. Drug Induced Liver Injury: Can Biomarkers Assist RUCAM in Causality Assessment? Int. J. Mol. Sci. 2017, 18, 803.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top